Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

[Background]: Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that its multimodal activity may be enhanced by programmed cell death protein 1 pathway inhibition and activation of T cell–m...

Descripción completa

Detalles Bibliográficos
Autores: Suvannasankha, Attaya, Bahlis, Nizar J., Trudel, Suzanne, Weisel, Katja, Koenecke, Christian, Oriol, Albert, Voorhees, Peter, Alonso, Aranzazu A., Callander, Natalie S., Mateos, Maria Victoria, Reddy, Nishitha, Hakim, Shawn, LaMacchia, John, Patel, Nashita, Williams, Danaé, Jewell, Roxanne C., Zhou, Xiangdong, Gupta, Ira, Opalinska, J., Nooka, Ajay
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/387906
Acceso en línea:http://hdl.handle.net/10261/387906
Access Level:acceso abierto
Palabra clave:Belantamab mafodotin
Pembrolizumab
Refractory multiple myeloma
Dose‐escalation
Dose‐ expansion
Benefit‐risk profile
Safety
Descripción
Sumario:[Background]: Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that its multimodal activity may be enhanced by programmed cell death protein 1 pathway inhibition and activation of T cell–mediated antitumor responses. This study investigated the efficacy and safety of belamaf with pembrolizumab in patients with RRMM.

Similares en LA Referencia